Free Trial

Elevation Oncology (ELEV) Stock Price, News & Analysis

Elevation Oncology logo
$0.36 0.00 (0.00%)
As of 07/23/2025

About Elevation Oncology Stock (NASDAQ:ELEV)

Key Stats

Today's Range
$0.37
$0.37
50-Day Range
$0.30
$0.39
52-Week Range
$0.22
$3.09
Volume
N/A
Average Volume
1.18 million shs
Market Capitalization
$21.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.39
Consensus Rating
Hold

Company Overview

Elevation Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ELEV MarketRank™: 

Elevation Oncology scored higher than 54% of companies evaluated by MarketBeat, and ranked 469th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elevation Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 11 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elevation Oncology has only been the subject of 4 research reports in the past 90 days.

  • Read more about Elevation Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Elevation Oncology are expected to decrease in the coming year, from ($0.84) to ($0.89) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elevation Oncology is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elevation Oncology is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elevation Oncology has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Elevation Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    3.92% of the float of Elevation Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevation Oncology has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevation Oncology has recently decreased by 31.58%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Elevation Oncology does not currently pay a dividend.

  • Dividend Growth

    Elevation Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.92% of the float of Elevation Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Elevation Oncology has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elevation Oncology has recently decreased by 31.58%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Elevation Oncology has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.08 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Elevation Oncology this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Elevation Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of Elevation Oncology is held by insiders.

  • Percentage Held by Institutions

    83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Elevation Oncology's insider trading history.
Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

ELEV Stock News Headlines

Elevation Oncology Terminates License Agreement with CSPC
AI Frenzy Could Send ‘EarnPhone’ Soaring
The hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and searches — are feeding the next wave of AI innovation. Big Tech is harvesting it. Mode Mobile is giving it back to you. They are creating a user-powered data economy that shares the upside, and +50M users have already generated +$325M in earnings. This isn't a theory… Mode’s 32,481% revenue growth from 2019-2022 landed them the #1 spot on Deloitte’s 2023 list of fastest growing companies in software, and they’ve secured the Nasdaq ticker $MODE ahead of a potential IPO. The offering could close any moment now. AI breakthroughs are everywhere, but these models need your data to survive. Invest in the company that allows you to share in the profits from yours.
See More Headlines

ELEV Stock Analysis - Frequently Asked Questions

Elevation Oncology's stock was trading at $0.5626 on January 1st, 2025. Since then, ELEV shares have decreased by 35.1% and is now trading at $0.3650.

Elevation Oncology, Inc. (NASDAQ:ELEV) announced its earnings results on Thursday, May, 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.04.

Elevation Oncology (ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

Top institutional investors of Elevation Oncology include Deltec Asset Management LLC (2.43%).
View institutional ownership trends
.

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevation Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
5/15/2025
Today
7/28/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELEV
CIK
1783032
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$0.70
Potential Upside/Downside
+827.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$44.49 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-74.68%
Return on Assets
-48.14%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
19.40
Quick Ratio
19.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.02 per share
Price / Book
0.36

Miscellaneous

Outstanding Shares
59,220,000
Free Float
54,427,000
Market Cap
$21.62 million
Optionable
Optionable
Beta
1.48
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ELEV) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners